CIRION BioPharma Research Inc. to offer SARS-CoV-2 and COVID-19 antibodies testing services
by CM Staff
The detection of the SARS-CoV-2 virus RNA is a prerequisite for the diagnosis of an acute infection with COVID-19
LAVAL, Que. — CIRION BioPharma Research Inc., a provider of large molecule bioanalytical testing and global central laboratory services, announced July 7 that the company is offering testing services for the screening and clinical diagnosis of COVID–19 and will be expanding its laboratory facilities by more than 7,500 square-feet.
The detection of the SARS-CoV-2 virus RNA is a prerequisite for the diagnosis of an acute infection with this new coronavirus (COVID-19). CIRION implemented the TaqPath COVID-19 Combo multiplex rt-PCR assay for the qualitative detection of nucleic acid from SARS-CoV-2 in upper respiratory tract specimens.
In addition, CIRION will be offering the Roche Diagnostics Elecsys Anti-SARS-CoV-2 immunoassay running on its testing platform for the qualitative detection of antibodies to SARS-CoV-2 in human serum and plasma. This assay is intended as an aid in the determination of the immune reaction to SARS-CoV-2 infection. These assays are approved as in-vitro diagnostic kit by the FDA and Health Canada authorities and are CE–marked.
According to a company statement, these new testing services are also offered to patients from public and private health organizations, for corporations interested in identifying infected employees to mitigate the business risk of an outbreak of COVID–19, and for international travelers to countries requiring certification of a negative SARS-CoV-2 test.
